THERACLION announces that it has signed a commercial partnership with the University of Virginia (UVA), in the United States, for the use of Theraclion's latest technology in a new experimental breast cancer treatment. This pilot study, which has received FDA (Food & Drug Administration) approval, will evaluate the combined effect of high intensity focused ultrasound (HIFU) and low dose chemotherapy on the immune response to breast cancer. The aim is to add HIFU into routine breast cancer treatment.

The HD technology has shown excellent clinical results in vein treatment. Its visualization capabilities and its very high control of acoustic energy deposition open up new prospects in the use of High Intensity Focused Ultrasound (HIFU) in breast cancer treatment. Building on a successful initial partnership in advanced breast cancer patients, the University of Virginia (UVA) Cancer Center has purchased Theraclion's latest HD technology to launch a pilot study for early breast cancer.

This protocol will evaluate the combined effect of Theraclion's focused ultrasound and low-dose chemotherapy in patients with early breast cancer. The 48-patient randomised trial will assess 3 arms: HIFU combined with chemotherapy, chemotherapy on its own and HIFU on its own. If the combination of HIFU and chemotherapy decreases myeloid-derived suppressor cells and thus increases the patient's immune response, this combination treatment could offer early breast cancer patients a better chance of survival.